A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction

Yuhong Zhou, Michael Shapiro, Qu Dong, Jamila Louahed, Christine Weiss, ShanHong Wan, Qiming Chen, Carl Dragwa, Dawn Savio, Minxue Huang, Catherine Fuller, Yaniv Tomer, Nicholas C. Nicolaides, Michael McLane, Roy C Levitt

Research output: Chapter in Book/Report/Conference proceedingChapter

59 Citations (Scopus)

Abstract

We have previously shown that expression of a Ca2+ -activated Cl- channel (mCLCA 3 in mice and hCLCA 1 in humans) is up-regulated along with goblet cell metaplasia and mucus overproduction in the lungs of interleukin 9 (IL9) transgenic mice, and in human primary lung cultures by IL4, IL13 and IL9. We show here that hCLCA 1 expression in NCI-H292 cells specifically induces soluble gel-forming mucin production. Moreover, niflumic acid (NFA), a blocker of hCLCA1-dependent Cl- efflux, inhibits MUC5A/C production in these cells. NFA treatment during natural antigen-exposure, where mCLCA3 is greatly up-regulated in the lung, significantly reduces airway inflammation, goblet cell metaplasia and mucus overproduction in vivo. These data suggest that this Ca2+ -activated Cl- channel plays an important role in epithelial-regulated inflammatory responses, including goblet cell metaplasia, and represents a potential novel therapeutic target for the control of mucus overproduction chronic pulmonary disorders.

Original languageEnglish
Title of host publicationNovartis Foundation Symposium
Pages150-170
Number of pages21
Volume248
StatePublished - Dec 1 2002
Externally publishedYes

Publication series

NameNovartis Foundation Symposium
Volume248

Fingerprint

Chloride Channels
Goblet Cells
Metaplasia
Mucus
Niflumic Acid
Interleukin-9
Lung
Interleukin-13
Mucins
Interleukin-4
Transgenic Mice
Gels
Inflammation
Antigens
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zhou, Y., Shapiro, M., Dong, Q., Louahed, J., Weiss, C., Wan, S., ... Levitt, R. C. (2002). A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction. In Novartis Foundation Symposium (Vol. 248, pp. 150-170). (Novartis Foundation Symposium; Vol. 248).

A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction. / Zhou, Yuhong; Shapiro, Michael; Dong, Qu; Louahed, Jamila; Weiss, Christine; Wan, ShanHong; Chen, Qiming; Dragwa, Carl; Savio, Dawn; Huang, Minxue; Fuller, Catherine; Tomer, Yaniv; Nicolaides, Nicholas C.; McLane, Michael; Levitt, Roy C.

Novartis Foundation Symposium. Vol. 248 2002. p. 150-170 (Novartis Foundation Symposium; Vol. 248).

Research output: Chapter in Book/Report/Conference proceedingChapter

Zhou, Y, Shapiro, M, Dong, Q, Louahed, J, Weiss, C, Wan, S, Chen, Q, Dragwa, C, Savio, D, Huang, M, Fuller, C, Tomer, Y, Nicolaides, NC, McLane, M & Levitt, RC 2002, A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction. in Novartis Foundation Symposium. vol. 248, Novartis Foundation Symposium, vol. 248, pp. 150-170.
Zhou Y, Shapiro M, Dong Q, Louahed J, Weiss C, Wan S et al. A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction. In Novartis Foundation Symposium. Vol. 248. 2002. p. 150-170. (Novartis Foundation Symposium).
Zhou, Yuhong ; Shapiro, Michael ; Dong, Qu ; Louahed, Jamila ; Weiss, Christine ; Wan, ShanHong ; Chen, Qiming ; Dragwa, Carl ; Savio, Dawn ; Huang, Minxue ; Fuller, Catherine ; Tomer, Yaniv ; Nicolaides, Nicholas C. ; McLane, Michael ; Levitt, Roy C. / A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction. Novartis Foundation Symposium. Vol. 248 2002. pp. 150-170 (Novartis Foundation Symposium).
@inbook{1f94c4331d4a4aa08fb004a0aae03938,
title = "A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction",
abstract = "We have previously shown that expression of a Ca2+ -activated Cl- channel (mCLCA 3 in mice and hCLCA 1 in humans) is up-regulated along with goblet cell metaplasia and mucus overproduction in the lungs of interleukin 9 (IL9) transgenic mice, and in human primary lung cultures by IL4, IL13 and IL9. We show here that hCLCA 1 expression in NCI-H292 cells specifically induces soluble gel-forming mucin production. Moreover, niflumic acid (NFA), a blocker of hCLCA1-dependent Cl- efflux, inhibits MUC5A/C production in these cells. NFA treatment during natural antigen-exposure, where mCLCA3 is greatly up-regulated in the lung, significantly reduces airway inflammation, goblet cell metaplasia and mucus overproduction in vivo. These data suggest that this Ca2+ -activated Cl- channel plays an important role in epithelial-regulated inflammatory responses, including goblet cell metaplasia, and represents a potential novel therapeutic target for the control of mucus overproduction chronic pulmonary disorders.",
author = "Yuhong Zhou and Michael Shapiro and Qu Dong and Jamila Louahed and Christine Weiss and ShanHong Wan and Qiming Chen and Carl Dragwa and Dawn Savio and Minxue Huang and Catherine Fuller and Yaniv Tomer and Nicolaides, {Nicholas C.} and Michael McLane and Levitt, {Roy C}",
year = "2002",
month = "12",
day = "1",
language = "English",
volume = "248",
series = "Novartis Foundation Symposium",
pages = "150--170",
booktitle = "Novartis Foundation Symposium",

}

TY - CHAP

T1 - A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction

AU - Zhou, Yuhong

AU - Shapiro, Michael

AU - Dong, Qu

AU - Louahed, Jamila

AU - Weiss, Christine

AU - Wan, ShanHong

AU - Chen, Qiming

AU - Dragwa, Carl

AU - Savio, Dawn

AU - Huang, Minxue

AU - Fuller, Catherine

AU - Tomer, Yaniv

AU - Nicolaides, Nicholas C.

AU - McLane, Michael

AU - Levitt, Roy C

PY - 2002/12/1

Y1 - 2002/12/1

N2 - We have previously shown that expression of a Ca2+ -activated Cl- channel (mCLCA 3 in mice and hCLCA 1 in humans) is up-regulated along with goblet cell metaplasia and mucus overproduction in the lungs of interleukin 9 (IL9) transgenic mice, and in human primary lung cultures by IL4, IL13 and IL9. We show here that hCLCA 1 expression in NCI-H292 cells specifically induces soluble gel-forming mucin production. Moreover, niflumic acid (NFA), a blocker of hCLCA1-dependent Cl- efflux, inhibits MUC5A/C production in these cells. NFA treatment during natural antigen-exposure, where mCLCA3 is greatly up-regulated in the lung, significantly reduces airway inflammation, goblet cell metaplasia and mucus overproduction in vivo. These data suggest that this Ca2+ -activated Cl- channel plays an important role in epithelial-regulated inflammatory responses, including goblet cell metaplasia, and represents a potential novel therapeutic target for the control of mucus overproduction chronic pulmonary disorders.

AB - We have previously shown that expression of a Ca2+ -activated Cl- channel (mCLCA 3 in mice and hCLCA 1 in humans) is up-regulated along with goblet cell metaplasia and mucus overproduction in the lungs of interleukin 9 (IL9) transgenic mice, and in human primary lung cultures by IL4, IL13 and IL9. We show here that hCLCA 1 expression in NCI-H292 cells specifically induces soluble gel-forming mucin production. Moreover, niflumic acid (NFA), a blocker of hCLCA1-dependent Cl- efflux, inhibits MUC5A/C production in these cells. NFA treatment during natural antigen-exposure, where mCLCA3 is greatly up-regulated in the lung, significantly reduces airway inflammation, goblet cell metaplasia and mucus overproduction in vivo. These data suggest that this Ca2+ -activated Cl- channel plays an important role in epithelial-regulated inflammatory responses, including goblet cell metaplasia, and represents a potential novel therapeutic target for the control of mucus overproduction chronic pulmonary disorders.

UR - http://www.scopus.com/inward/record.url?scp=0038011900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038011900&partnerID=8YFLogxK

M3 - Chapter

C2 - 12568493

AN - SCOPUS:0038011900

VL - 248

T3 - Novartis Foundation Symposium

SP - 150

EP - 170

BT - Novartis Foundation Symposium

ER -